162 related articles for article (PubMed ID: 37312213)
41. Salvage stereotactic ablative irradiation for isolated postsurgical local recurrence of lung cancer.
Takeda A; Sanuki N; Eriguchi T; Enomoto T; Yokosuka T; Kaneko T; Handa H; Aoki Y; Oku Y; Kunieda E
Ann Thorac Surg; 2013 Nov; 96(5):1776-82. PubMed ID: 23998410
[TBL] [Abstract][Full Text] [Related]
42. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
[TBL] [Abstract][Full Text] [Related]
43. Clinical Outcomes of Stereotactic Ablative Radiotherapy for All Stages of Non-Small Cell Lung Cancer; Definitive versus Consolidative.
Kim H; Kim SM; Yang DS; Lee KH; Kim YB
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143981
[No Abstract] [Full Text] [Related]
44. Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial.
Cruz-Lim EM; Mou B; Jiang W; Liu M; Bergman A; Schellenberg D; Alexander A; Berrang T; Bang A; Chng N; Matthews Q; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Huang V; Mestrovic A; Hyde D; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson R; Baker S
Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):141-147. PubMed ID: 38296662
[TBL] [Abstract][Full Text] [Related]
45. Feasibility of split-course stereotactic ablative radiotherapy for oligometastases.
Paik EK; Kim MS; Seo YS; Jang WI; Kang JK; Cho CK; Yoo HJ
Jpn J Clin Oncol; 2018 Jun; 48(6):548-554. PubMed ID: 29722825
[TBL] [Abstract][Full Text] [Related]
46. Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by
Mazzola R; Fiorentino A; Di Paola G; Giaj Levra N; Ricchetti F; Fersino S; Tebano U; Pasetto S; Ruggieri R; Salgarello M; Alongi F
J Thorac Oncol; 2017 Mar; 12(3):547-555. PubMed ID: 28126325
[TBL] [Abstract][Full Text] [Related]
47. Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).
Oskan F; Dzierma Y; Wagenpfeil S; Rübe C; Fleckenstein J
J Thorac Dis; 2017 Mar; 9(3):742-756. PubMed ID: 28449482
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcomes and lung toxicities after lung SABR using dynamic conformal arc therapy: a single-institution cohort study.
Mesny E; Ayadi M; Dupuis P; Beldjoudi G; Tanguy R; Martel-Lafay I
Radiat Oncol; 2023 Feb; 18(1):36. PubMed ID: 36814265
[TBL] [Abstract][Full Text] [Related]
49. Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study.
Filippi AR; Badellino S; Ceccarelli M; Guarneri A; Franco P; Monagheddu C; Spadi R; Ragona R; Racca P; Ricardi U
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):524-9. PubMed ID: 25542308
[TBL] [Abstract][Full Text] [Related]
50. Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience.
Thibault I; Poon I; Yeung L; Erler D; Kim A; Keller B; Lochray F; Jain S; Soliman H; Cheung P
Clin Oncol (R Coll Radiol); 2014 Nov; 26(11):713-9. PubMed ID: 25085765
[TBL] [Abstract][Full Text] [Related]
51. Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins.
Rwigema JC; Heron DE; Parikh SD; Zeh HJ; Moser JA; Bahary N; Ashby K; Burton SA
J Gastrointest Cancer; 2012 Mar; 43(1):70-6. PubMed ID: 20809393
[TBL] [Abstract][Full Text] [Related]
52. Clinical benefits of pulmonary resection for lung metastases from pancreatic cancer.
Konishi T; Takano S; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Hosokawa I; Mishima T; Nishino H; Nakada S; Ohtsuka M
Langenbecks Arch Surg; 2023 Dec; 409(1):11. PubMed ID: 38108917
[TBL] [Abstract][Full Text] [Related]
53. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
54. SABR for aggressive local therapy of metastatic cancer: A new paradigm for metastatic non-small cell lung cancer.
Westover KD; Iyengar P; Sharma AN; Timmerman R
Lung Cancer; 2015 Aug; 89(2):87-93. PubMed ID: 26028304
[TBL] [Abstract][Full Text] [Related]
55. SABR-BRIDGE:
Kidane B; Spicer J; Kim JO; Fiset PO; Abdulkarim B; Malthaner R; Palma D
Front Oncol; 2020; 10():580189. PubMed ID: 33072612
[TBL] [Abstract][Full Text] [Related]
56. Single-fraction stereotactic ablative body radiotherapy for sternal metastases in oligometastatic breast cancer: Technique and single institution experience.
Li MP; Kelly D; Tan J; Siva S; Kron T; David S
J Med Imaging Radiat Oncol; 2020 Aug; 64(4):580-585. PubMed ID: 32588550
[TBL] [Abstract][Full Text] [Related]
57. Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Eufemon Cereno R; Mou B; Baker S; Chng N; Arbour G; Bergman A; Liu M; Schellenberg D; Matthews Q; Huang V; Mestrovic A; Hyde D; Alexander A; Carolan H; Hsu F; Miller S; Atrchian S; Chan E; Ho C; Mohamed I; Lin A; Berrang T; Bang A; Jiang W; Lund C; Pai H; Valev B; Lefresne S; Tyldesley S; Olson RA
Radiother Oncol; 2023 May; 182():109576. PubMed ID: 36822355
[TBL] [Abstract][Full Text] [Related]
58. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis.
Senthi S; Lagerwaard FJ; Haasbeek CJ; Slotman BJ; Senan S
Lancet Oncol; 2012 Aug; 13(8):802-9. PubMed ID: 22727222
[TBL] [Abstract][Full Text] [Related]
59. Comparison of Single-fraction and Multi-fraction Stereotactic Radiotherapy for Patients with 18F-fluorodeoxyglucose Positron Emission Tomography-staged Pulmonary Oligometastases.
Siva S; Kirby K; Caine H; Pham D; Kron T; Te Marvelde L; Whalley D; Stevens MJ; Foroudi F; MacManus M; Ball D; Eade T
Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):353-61. PubMed ID: 25698068
[TBL] [Abstract][Full Text] [Related]
60. Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review.
Gouveia AG; Chan DCW; Hoskin PJ; Marta GN; Trippa F; Maranzano E; Chow E; Silva MF
Radiother Oncol; 2021 Oct; 163():55-67. PubMed ID: 34333087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
